Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IMVT investors who lost money.
NEW YORK, Sept. 25, 2026 /PRNewswire/ -- A missed primary endpoint took Immunovant (NASDAQ: IMVT) down roughly 6% on September 23, 2026 -- to the stock's lowest level in more than three months. If you lost money holding IMVT, you are encouraged to see whether you can recover your losses. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.
The selling started before the opening bell. Immunovant disclosed that its proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not meet its prespecified primary endpoint, and that the cutaneous lupus program was being discontinued. Shares moved lower in premarket trading and the stock traded to a more-than-three-month low, according to multiple published reports.
Days earlier, the market was pricing the shares very differently. Reports on September 18 through September 20, 2026 described IMVT trading at approximately $36.95, a market capitalization of roughly $7.63 billion, and investor attention focused on upcoming clinical data. IMVT-1402 had been identified as the Company's lead development program.
Immunovant investors who took losses in the September 23 decline can request a no-cost review of their IMVT losses. You may also reach Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the IMVT Investigation
Q: How much did IMVT stock drop?A: Shares fell approximately 6% on September 23, 2026, reaching a more-than-three-month low, after the Company disclosed that its IMVT-1402 proof-of-concept study in cutaneous lupus erythematosus missed its primary endpoint and that the cutaneous lupus program was being discontinued. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek recovery.
Q: Which statements are being investigated as potentially misleading?A: The investigation concerns whether Immunovant made materially false or misleading statements regarding the clinical prospects of IMVT-1402, its lead development program, including in cutaneous lupus erythematosus. When the Company disclosed the primary endpoint miss and the discontinuation of the lupus program, the stock price declined sharply.
Q: What do IMVT investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What is a lead plaintiff and why does it matter?A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.
Q: What if I already sold my IMVT shares -- can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IMVT and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
Tel: (888) SueWallSt\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunovant-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-immunovant-imvt-302889915.html
SOURCE SueWallSt.com
